OCTN1 Mediates Acetylcholine Transport in the A549 Lung Cancer Cells: Possible Pathophysiological Implications

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2024 Dec 25

PMID 39719963

Authors

Lorena Pochini

Giusi Elisabetta Tedesco

Tiziano Mazza

Mariafrancesca Scalise

Cesare Indiveri

Affiliations

Soon will be listed here.

Abstract

A role for acetylcholine in cell proliferation, epithelial mesenchymal transition and invasion has been well assessed and related to the presence of the non-neuronal cholinergic system in lung cancer. For the operation of this non-neuronal system, acetylcholine should be released by a transporter mediated non-quantal process. OCTN1 is one of the transporters able to catalyse acetylcholine efflux and . Using the A549 cell line as a lung cancer model, it has been found that these cells express OCTN1 at a higher level with respect to other cancer cells. The transport capacity of OCTN1 extracted from A549 and reconstituted into proteoliposomes reflects the protein expression profile. The properties of the acetylcholine transport mediated by OCTN1 of A549 in terms of specificity to ligands and ability to catalyse efflux of acetylcholine correspond to those previously described for the same transporter in other cells or to those of the human recombinant protein. OCTN1 is the major player in acetylcholine release in A549 and, therefore, may represent a target for inhibitors able to block the acetylcholine action in this type of aggressive tumors.

References

Chen J, Cheuk I, Shin V, Kwong A . Acetylcholine receptors: Key players in cancer development. Surg Oncol. 2019; 31:46-53. DOI: 10.1016/j.suronc.2019.09.003. View

Pochini L, Scalise M, Indiveri C . Immuno-detection of OCTN1 (SLC22A4) in HeLa cells and characterization of transport function. Int Immunopharmacol. 2015; 29(1):21-6. DOI: 10.1016/j.intimp.2015.04.040. View

Friedman J, Richbart S, Merritt J, Brown K, Nolan N, Akers A . Acetylcholine signaling system in progression of lung cancers. Pharmacol Ther. 2018; 194:222-254. PMC: 6348061. DOI: 10.1016/j.pharmthera.2018.10.002. View

Drenberg C, Gibson A, Pounds S, Shi L, Rhinehart D, Li L . OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017; 77(8):2102-2111. PMC: 5419029. DOI: 10.1158/0008-5472.CAN-16-2548. View

Gomes M, Teixeira A, Coelho A, Araujo A, Medeiros R . The role of inflammation in lung cancer. Adv Exp Med Biol. 2014; 816:1-23. DOI: 10.1007/978-3-0348-0837-8_1. View

Tan Z, Xue H, Sun Y, Zhang C, Song Y, Qi Y . The Role of Tumor Inflammatory Microenvironment in Lung Cancer. Front Pharmacol. 2021; 12:688625. PMC: 8166205. DOI: 10.3389/fphar.2021.688625. View

Banzato R, Pinheiro N, Olivo C, Santana F, Lopes F, Caperuto L . Long-term endogenous acetylcholine deficiency potentiates pulmonary inflammation in a murine model of elastase-induced emphysema. Sci Rep. 2021; 11(1):15918. PMC: 8342425. DOI: 10.1038/s41598-021-95211-3. View

Salomon J, Endter S, Tachon G, Falson F, Buckley S, Ehrhardt C . Transport of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) in human respiratory epithelial cells. Eur J Pharm Biopharm. 2012; 81(2):351-9. DOI: 10.1016/j.ejpb.2012.03.001. View

Zoli M, Pucci S, Vilella A, Gotti C . Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors. Curr Neuropharmacol. 2017; 16(4):338-349. PMC: 6018187. DOI: 10.2174/1570159X15666170912110450. View

10.

Pochini L, Scalise M, Di Silvestre S, Belviso S, Pandolfi A, Arduini A . Acetylcholine and acetylcarnitine transport in peritoneum: Role of the SLC22A4 (OCTN1) transporter. Biochim Biophys Acta. 2016; 1858(4):653-60. DOI: 10.1016/j.bbamem.2015.12.026. View

11.

Pochini L, Barone F, Console L, Brunocilla C, Galluccio M, Scalise M . OCTN1 (SLC22A4) displays two different transport pathways for organic cations or zwitterions. Biochim Biophys Acta Biomembr. 2023; 1866(2):184263. DOI: 10.1016/j.bbamem.2023.184263. View

12.

Wang W, Gallo L, Jadhav A, Hawkins R, Parker C . The Druggability of Solute Carriers. J Med Chem. 2019; 63(8):3834-3867. DOI: 10.1021/acs.jmedchem.9b01237. View

13.

Sales M, Espanol A, Salem A, Pulido P, Sanchez Y, Sanchez F . Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy. Curr Clin Pharmacol. 2018; 14(2):91-100. PMC: 7011678. DOI: 10.2174/1574884714666181203095437. View

14.

Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi P . Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Cancers (Basel). 2022; 14(19). PMC: 9558974. DOI: 10.3390/cancers14194562. View

15.

Hiraizumi M, Akashi T, Murasaki K, Kishida H, Kumanomidou T, Torimoto N . Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter. Nat Struct Mol Biol. 2023; 31(1):159-169. PMC: 10803289. DOI: 10.1038/s41594-023-01134-0. View

16.

Pochini L, Scalise M, Galluccio M, Amelio L, Indiveri C . Reconstitution in liposomes of the functionally active human OCTN1 (SLC22A4) transporter overexpressed in Escherichia coli. Biochem J. 2011; 439(2):227-33. DOI: 10.1042/BJ20110544. View

17.

Nishikubo K, Ohgaki R, Okanishi H, Okuda S, Xu M, Endou H . Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells. J Cell Mol Med. 2022; 26(20):5246-5256. PMC: 9575050. DOI: 10.1111/jcmm.17553. View

18.

Berg T, Hegelund-Myrback T, Ockinger J, Zhou X, Brannstrom M, Hagemann-Jensen M . Expression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals. Respir Res. 2018; 19(1):68. PMC: 5910606. DOI: 10.1186/s12931-018-0760-9. View

19.

Islas-Weinstein L, Marquina-Castillo B, Mata-Espinosa D, Paredes-Gonzalez I, Chavez J, Balboa L . The Cholinergic System Contributes to the Immunopathological Progression of Experimental Pulmonary Tuberculosis. Front Immunol. 2021; 11:581911. PMC: 7930380. DOI: 10.3389/fimmu.2020.581911. View

20.

Singh I, Seth A, Billesbolle C, Braz J, Rodriguiz R, Roy K . Structure-based discovery of conformationally selective inhibitors of the serotonin transporter. Cell. 2023; 186(10):2160-2175.e17. PMC: 10306110. DOI: 10.1016/j.cell.2023.04.010. View